Characterization of Three CYP2C19 Gene Variants by MassARRAY and Point of Care Techniques: Experience from a Czech Centre

Original Article

DOI: 10.1007/s00005-016-0440-8

Cite this article as:
Petrek, M., Kocourkova, L., Zizkova, V. et al. Arch. Immunol. Ther. Exp. (2016) 64(Suppl 1): 99. doi:10.1007/s00005-016-0440-8


Distribution of cytochrome P450 2C19 enzyme gene (CYP2C19) variants affecting metabolism of clopidogrel was determined in 526 Czech patients after percutaneous coronary intervention using MassARRAY genotyping and compared to distribution in other populations of European descent. Fifty-three (10%) patients underwent parallel determination of CYP2C19 genotypes from buccal swabs by a point of care technique with 100% concordance to the main genotyping platform. Observed CYP2C19 genotypes were related to clopidogrel metabolism phenotypes and discussed in population context. Hereby, presented methodologies provide accurate CYP2C19 genotyping results in a relatively short time of one up to 12 h and may, therefore, find the relevant place in the field of genotype-guided antiplatelet therapy.


CYP2C19 Pharmacogenetics Clopidogrel Genotyping Point of care 

Copyright information

© L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland 2016

Authors and Affiliations

  1. 1.Laboratory of Cardiogenomics-LEMUniversity Hospital OlomoucOlomoucCzech Republic
  2. 2.Faculty of Medicine and Dentistry, Institute of Molecular and Translational MedicinePalacký University OlomoucOlomoucCzech Republic
  3. 3.Department of Pathological Physiology, Faculty of Medicine and DentistryPalacký University OlomoucOlomoucCzech Republic
  4. 4.Department of Internal Medicine-Cardiology, Faculty of Medicine and DentistryPalacký University and University Hospital OlomoucOlomoucCzech Republic

Personalised recommendations